Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis

References

• SandsBETremaineWJSandbornWJInfliximab in the treatment of severe steroid-refractory ulcerative colitis: A pilot studyInflammatory Bowel Dis200178388
   PubMed Web of Science ®Google Scholar
• GornetJMCouveSHassaniZInfliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre studyAliment Pharmacol Ther200318217518112869077
   PubMed Web of Science ®Google Scholar
• DignassALindsayJOSturmASecond European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current managementJ Crohns Colitis2012610991103023040451
   PubMed Web of Science ®Google Scholar
• TraceyDKlareskogLSassoEHSalfeldJGTakPPTumor necrosis factor antagonist mechanisms of action: a comprehensive reviewPharmacol Ther2008117224427918155297
   PubMed Web of Science ®Google Scholar
• REMICADE® (infliximab) [package insert]Horsham, PAJanssen Biotech, Inc2013
   Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353232462224716339095
   PubMed Web of Science ®Google Scholar
• FerranteMVermeireSFidderHLong-term outcome after infliximab for refractory ulcerative colitisJ Crohns Colitis20082321922521172214
   PubMed Web of Science ®Google Scholar
• ArmuzziAPuglieseDDaneseSInfliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remissionInflamm Bowel Dis20131951065107223448790
   PubMed Web of Science ®Google Scholar
• ArmuzziAPuglieseDDaneseSLong-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitisInflamm Bowel Dis20142081368131324983979
   PubMed Web of Science ®Google Scholar
• HUMIRA® (adalimumab) [package insert]North Chicago, ILAbbVie Inc2015
   Google Scholar
• ReinischWSandbornWJHommesDWAdalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut201160678078721209123
   PubMed Web of Science ®Google Scholar
• SandbornWJvan AsscheGReinischWAdalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitisGastroenterology2012142225726522062358
   PubMed Web of Science ®Google Scholar
• ArmuzziABianconeLDapernoMItalian Group for the Study of Inflammatory Bowel Disease. Adalimumab in active ulcerative colitis: a “real-life” observational studyDig Liver Dis201345973874323683530
   PubMedGoogle Scholar
• Ben-HorinSKopylovUChowersYOptimizing anti-TNF treatments in inflammatory bowel diseaseAutoimmun Rev2014131243023792214
   PubMed Web of Science ®Google Scholar
• AllezMKarmirisKLouisEReport of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspectsJ Crohns Colitis20104435536621122530
   PubMed Web of Science ®Google Scholar
• LangholzEMunkholmPDavidsenMBinderVCourse of ulcerative colitis: analysis of changes in disease activity over yearsGastroenterology19941073118020674
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGMaranoCPURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisGastroenterology20141461859523735746
   PubMed Web of Science ®Google Scholar
• RutgeertsPFeaganBGMaranoCWPURSUIT-IV study group. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitisAliment Pharmacol Ther20154250451426119226
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGMaranoCPURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisGastroenterology201414619610923770005
   PubMed Web of Science ®Google Scholar
• ShealyDCaiAStaquetKCharacterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor αMAbs20102442843920519961
   PubMed Web of Science ®Google Scholar
• SIMPONI® (golimumab) [package insert]Horsham, PAJanssen Biotech, Inc2015
   Google Scholar
• SchroederKWTremaineWJIlstrupDMCoated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized studyN Engl J Med1987317162516293317057
   PubMed Web of Science ®Google Scholar
• IrvineEJFeaganBRochonJQuality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study GroupGastroenterology19941062872968299896
   PubMed Web of Science ®Google Scholar
• ColombelJReinischWGibsonPClinical outcomes in continuous clinical responders with moderately to severely active ulcerative colitis: sub-analysis from the PURSUIT-SC MANTEINANCE StudyUnited European Gastroenterol J20142S1A376
   Google Scholar
• FeaganBGibsonWReinischWLong-term safety and efficacy of Golimumab in patients with moderately to severely active ulcerative colitis: results from the PURSUIT-SC maintenance study extensionCan J Gastroenterol201529SAA263
   Google Scholar
• PanaccioneRRutgeertsPSandbornWJFeaganBSchreiberSGhoshSReview article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel diseaseAliment Pharmacol Ther200828667468818532990
   PubMed Web of Science ®Google Scholar
• JewellDPTrueloveSCAzathioprine in ulcerative colitis: an interim report on a controlled therapeutic trialBr Med J1972158027097124552464
   PubMed Web of Science ®Google Scholar
• CaprilliRCarratùRBabbiniMDouble-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary reportAm J Dig Dis1975202115120235835
   PubMedGoogle Scholar
• SoodAMidhaVSoodNKaushalVRole of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trialIndian J Gastroenterol2000191141610659481
   PubMedGoogle Scholar
• ArdizzoneSMaconiGRussoAImbesiVColomboEBianchi PorroGRandomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitisGut2006551475315972298
   PubMed Web of Science ®Google Scholar
• DignassAEliakimRMagroFEuropean evidence-based consensus on the diagnosis and management of ulcerative colitis part 1 definitions and diagnosisJ Crohns Colitis2012696599023040452
   PubMed Web of Science ®Google Scholar
• StidhamRWLeeTCHigginsPDSystematic review with network meta-analysis:the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitisAliment Pharmacol Ther201439766067124506179
   PubMed Web of Science ®Google Scholar
• ProbertCSHearingSDSchreiberSKühbacherTInfliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trialGut2003527998100212801957
   PubMed Web of Science ®Google Scholar
• ThorlundKDruytsEToorKMillsEJComparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designsExpert Rev Gastroenterol Hepatol20159569370025763862
   PubMed Web of Science ®Google Scholar
• SylwestrzakGLiuJStephensonJJRuggieriAPDeVriesAConsidering patient preferences when selecting anti-tumor necrosis factor therapeutic optionsAm Health Drug Benefits201472718124991392
   PubMedGoogle Scholar
• KeystoneECGenoveseMCHallSGolimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extensionJ Rheumatol20134071097110323678153
   PubMed Web of Science ®Google Scholar
• SmolenJSKayJDoyleMGolimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER studyArthritis Res Ther2015171425627338
   PubMed Web of Science ®Google Scholar
• KavanaughAMcInnesIBMeasePClinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)Ann Rheum Dis20147391689169424748630
   PubMed Web of Science ®Google Scholar
• DeodharABraunJInmanRDGolimumab administered subcutaneously every 4 weeks in ankylosing spondylitis:5-year results of the GO-RAISE studyAnn Rheum Dis201574475776125387477
   PubMed Web of Science ®Google Scholar